VRDN
Viridian Therapeutics Inc
NASDAQ: VRDN · HEALTHCARE · BIOTECHNOLOGY
$13.48
+1.35% today
Updated 2026-04-30
Market cap
$1.37B
P/E ratio
—
P/S ratio
19.35x
EPS (TTM)
$-3.32
Dividend yield
—
52W range
$12 – $34
Volume
2.3M
Viridian Therapeutics Inc (VRDN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-6.22M | $-1.17M | $-2.21M | $-6.90M | $-7.23M | $-28.17M | $-26.84M | $-36.06M | $-29.78M | $-54.58M | $-93.84M | $-184.17M | $-232.32M | $-276.39M |
| Capital expenditures | $106913.00 | $4769.00 | $266000.00 | $123000.00 | $3000.00 | $246000.00 | $445000.00 | $84000.00 | $42000.00 | $338000.00 | $797000.00 | $898000.00 | $511000.00 | $495000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $7955.00 | — | $4.30M | $3.02M | $2.11M | $2.41M | $3.68M | $3.97M | $3.65M | $14.46M | $19.77M | $67.17M | $42.15M | $44.30M |
| Free cash flow | $-6.33M | $-1.17M | $-2.48M | $-7.02M | $-7.23M | $-28.41M | $-27.29M | $-36.14M | $-29.82M | $-54.92M | $-94.64M | $-185.07M | $-232.83M | $-276.89M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | $720000.00 | $285000.00 | — | — | — | — | — | — | $44000.00 | — | — | $14.49M | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | $21.05M | $-3.60M | $113.28M | — | — | — |